Entrada Therapeutics Inc [TRDA] stock prices are down -0.40% to $10.08 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TRDA shares have gain 15.46% over the last week, with a monthly amount glided 37.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Entrada Therapeutics Inc [NASDAQ: TRDA] stock has seen the most recent analyst activity on December 06, 2024, when ROTH MKM initiated its Buy rating and assigned the stock a price target of $29. Previously, Oppenheimer started tracking the stock with Outperform rating on January 05, 2024, and set its price target to $22. On April 03, 2023, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock.
The stock price of Entrada Therapeutics Inc [TRDA] has been fluctuating between $4.93 and $21.79 over the past year. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Entrada Therapeutics Inc [NASDAQ: TRDA] shares were valued at $10.08 at the most recent close of the market. An investor can expect a potential return of 28.97% based on the average TRDA price forecast.
Analyzing the TRDA fundamentals
The Entrada Therapeutics Inc [NASDAQ:TRDA] reported sales of 61.52M for trailing twelve months, representing a drop of -91.75% . Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -1.98%, Pretax Profit Margin comes in at -1.7%, and Net Profit Margin reading is -1.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.26 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.92 points at the first support level, and at 9.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.28, and for the 2nd resistance point, it is at 10.49.
Ratios To Look Out For
It’s worth pointing out that Entrada Therapeutics Inc [NASDAQ:TRDA]’s Current Ratio is 14.08. In addition, the Quick Ratio stands at 14.08 and the Cash Ratio stands at 3.88. Considering the valuation of this stock, the price to sales ratio is 6.26, the price to book ratio is 1.13.
Transactions by insiders
Recent insider trading involved WENTWORTH KORY JAMES, Chief Financial Officer, that happened on Nov 21 ’25 when 8910.0 shares were sold. 10% Owner, BAKER BROS. ADVISORS LP completed a deal on Nov 20 ’25 to buy 28867.0 shares. Meanwhile, Officer KORY WENTWORTH bought 8910.0 shares on Nov 21 ’25.
